Free Webinar: Efficient Patient Identification in ALS Clinical Trials

In collaboration with Julius Clinical, TRICALS will present the webinar: “Efficient Patient…

Words Lucie van Leeuwen.Published November 3, 2020
Free Webinar: Efficient Patient Identification in ALS Clinical Trials

In collaboration with Julius Clinical, TRICALS will present the webinar:Efficient Patient Identification in ALS Clinical Trials; Leveraging the Concept of Fast and Slow Progressors”. The webinar will take place on November 10, 2020 at 18:00 CET.

We are pleased to announce that this webinar will be presented by: Prof. Dr. Leonard van den Berg (Professor of Neurology and Chair of TRICALS) and Dr. Ruben van Eijk (Assistant Professor and Medical Statistician) from our TRICALS Centre at UMC Utrecht, the Netherlands.

Topics that will be covered, include:

  • Prediction-based inclusion criteria
  • Defining the concept of fast vs slow progressors
  • Addressing disease heterogeneity and reduce variance
  • Regulatory perspective (EMA) on prediction-based patient selection

Don’t miss this opportunity and register now by clicking the link: https://bit.ly/3oAnz2L. The webinar will be recorded, so even if you can’t make it, make sure to sign up to receive the replay!


Share

Related news

European Commission approves Tofersen as treatment for ALS-SOD1
European Commission approves Tofersen as treatment for ALS-SOD1
The European Commission has approved the drug QALSODY, better known as Tofersen. […]
Amylyx terminates open-label extension of the PHOENIX study
Amylyx terminates open-label extension of the PHOENIX study
The pharmaceutical company Amylyx has announced that they will terminate the open-label […]
Meet the centre - Torino ALS Center (University of Torino)
Meet the centre - Torino ALS Center (University of Torino)
The TRICALS consortium currently consists of more than 40 centers across Europe. […]
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]